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Abstract
The a6b4 integrin plays a significant role in tumor growth, angiogenesis and metastasis through modulation of growth
factor signaling, and is a potentially important therapeutic target. However, a6b4-mediated cell-matrix adhesion is critical in
normal keratinocyte attachment, signaling and anchorage to the basement membrane through its interaction with laminin-
5, raising potential risks for targeted therapy. Bioengineered Human Skin Equivalent (HSE), which have been shown to
mimic their normal and wounded counterparts, have been used here to investigate the consequences of targeting b4t o
establish toxic effects on normal tissue homeostasis and epithelial wound repair. We tested two antibodies directed to
different b4 epitopes, one adhesion-blocking (ASC-8) and one non-adhesion blocking (ASC-3), and determined that these
antibodies were appropriately localized to the basal surface of keratinocytes at the basement membrane interface where b4
is expressed. While normal tissue architecture was not altered, ASC-8 induced a sub-basal split at the basement membrane
in non-wounded tissue. In addition, wound closure was significantly inhibited by ASC-8, but not by ASC-3, as the epithelial
tongue only covered 40 percent of the wound area at 120 hours post-wounding. These results demonstrate b4 adhesion-
blocking antibodies may have adverse effects on normal tissue, whereas antibodies directed to other epitopes may provide
safer alternatives for therapy. Taken together, we conclude that these three-dimensional tissue models provide a
biologically relevant platform to identify toxic effects induced by candidate therapeutics, which will allow generation of
findings that are more predictive of in vivo responses early in the drug development process.
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Introduction
Integrins are heterodimeric cell surface adhesion receptors
expressed on most cells throughout the body where they mediate
cell-cell and cell-extracellular matrix interactions [1]. They consist
of a and b subunits that associate in various combinations to form
at least 25 receptors. Each ab combination possesses specific
binding and signaling properties. Integrins are receptors for
extracellular matrices that transmit mechanical and biochemical
signals to regulate cellular functions including survival, prolifera-
tion, motility, transcription and protein translation [2,3]. In
normal tissues, a6b4 plays a role in the maintenance of epithelial
integrity, particularly in the epidermis where as a component of
the hemidesmosome complex, it serves to anchor basal keratino-
cytes to the underlying basement membrane through its
interaction with laminin-5 or laminin-322 according to the new
laminin nomenclature [4] and other proteins of the complex [5].
These interactions are destabilized when hemidesmosome disas-
sembly is required, for instance, to allow keratinocyte migration
during wound healing, a process regulated through cooperation
between b4 and growth factor mediated signaling [6].
In the last decade, experimental evidence has emerged that
integrins are involved in cancer growth, angiogenesis and
metastasis, and several antibodies targeting integrins are being
clinically evaluated as treatments for cancer. Integrins influence
tumor progression by modifying various intracellular signaling
pathways. a6b4, in particular, has been shown to cooperate in
growth factor mediated signaling [7]. Integrin a6b4 enhances pro-
tumor functions, such as migration, invasion, and resistance to
apoptotic stimuli [8]. In in vivo animal models, a6b4-signaling was
found to promote the onset of pathologic angiogenesis and
tumorigenesis [9,10]. In these experiments, the growth of
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Furthermore, a6b4 expression is increased in several types of
invasive and metastatic human carcinomas including breast,
colon, thyroid, gastric, bladder and squamous cell carcinomas
[8,11]. Because of this putative role in cancer, we and others have
proposed b4 as a potentially important therapeutic target that may
be amenable to an antibody blocking approach. However, the
consequences of targeting a6b4 integrin with an antibody on
normal tissue homeostasis and repair processes haven’t been yet
studied.
In order to assess potential secondary effects of blocking a6b4
on human stratified squamous epithelium, we utilized bioengi-
neered three-dimensional tissues that mimic human skin known as
human skin equivalents (HSEs). We have previously described the
development of HSEs, in which epidermal cells are grown at an
air–liquid interface on a connective tissue substrate harboring
viable fibroblasts [12]. In these three-dimensional tissues, HSEs
express basement membrane components, such as b4 and laminin-
5, recapitulating the organization of basement membrane in
human stratified squamous epithelium. Moreover, we adapted
HSEs to study wound repair in a manner that simulates the
chronology of events that occur during re-epithelialization in
human skin [13,14]. These HSEs enable direct determination of
phenotypic response of a wounded epithelium including cell
proliferation, migration, differentiation, growth-factor response,
and protease expression of epithelial and stromal cells.
Importantly, these tissues now serve as platforms for the rapid
screening of the potential efficacy or toxicity of human
therapeutics.
We previously demonstrated that an antibody (ASC-3) directed
to b4 could prevent anchorage-independent growth of breast
tumor cells in preclinical assays [15]. The activity and epitope of
this antibody was distinguishable from an adhesion blocking
antibody (ASC-8) that disrupts b4 interactions with laminin-5, but
does not affect growth in soft agar. We used three-dimensional
tissues as a platform to test the consequences of targeting b4 with
these antibodies, which are specific to human b4, first in a static
three-dimensional tissue model of non-wounded human epitheli-
um and second in a dynamic three-dimensional tissue model of
wound healing. When these antibodies were added to the culture
medium of HSEs, they adhered to the basement membrane zone
at the interface between the connective tissue and basal
keratinocytes, demonstrating appropriate localization of the
antibody to areas expressing the b4 subunit. However, while
ASC-8 caused detachment of the epithelium from the underlying
stroma and significantly blocked wound reepithelialization, ASC-3
neither blocked adhesion nor disrupted wound closure. This was
partially explained by the finding that ASC-8, but not ASC-3,
significantly decreased the migration rate of human keratinocytes
in two-dimensional cultures and was associated with a reduction in
cellular proliferation in the three-dimensional wound healing
model. These results indicate that therapeutic targeting with b4
blocking antibodies that disrupt cell adhesion to laminin-5 could
have potentially adverse side effects on normal tissue homeostasis
and wound repair. Furthermore, this study demonstrates the utility
of human, three-dimensional tissue platforms to screen the
function of antibodies directed to different epitopes. These
platforms show promise in efficiently and economically enabling
determination of the safety profile of candidate therapeutic agents.
Materials and Methods
All the cells used in this study have been isolated and published
previously [12–14,16].
Adhesion assays to determine ASC-3 and ASC-8 binding
to laminin-5
For cellular adhesion assays, Human Foreskin Keratinocytes
and an immortalized keratinocyte cell line (HACAT) were first
grown in serum-free medium (Dulbecco’s Modified Eagle
Medium, Invitrogen) for 24 hours. Cells were harvested using cell
dissociation buffer (Invitrogen) and resuspended at 1106 cells/ml
in Leibovitz L-15 medium (Invitrogen). For antibody treatments,
10 mg/ml of ASC-3 or ASC-8 (Chemicon) were added to the
resuspended cells, and incubated for 1 hr on ice. Cells were then
plated on 96-well plate that were precoated with 10 mg/ml rat
laminin-5 (Millipore), or a mixture of human laminins (Sigma), at
1610
5 cells per well and incubated for 1 hr at 4uC. After washing
the plates with Leibovitz L-15 medium, adherent cells were
quantified using Cell Titer Glo cell viability assay (Promega) and
luminescence reading on a SpectraMax M5 plate reader.
Flow Cytometry
Cells were harvested using cell dissociation buffer (Invitrogen),
washed and resuspended in FACS wash buffer (PBS) containing
10% normal goat serum (Invitrogen), 0.2% Bovine Serum
Albumin (Sigma), 0.1% NaN3 (Sigma) at a concentration of
1610
6 cells/well. Antibodies were diluted in FACS wash buffer
and incubated with the cells for 1 hr on ice, followed by washing
and incubation with a phycoerythrin-conjugated goat anti-mouse
secondary antibody for 1 hr on ice. Cells were washed again and
resuspended in FACS wash buffer containing 1 ug/ml propidium
iodide (PI) (Molecular Probes, Eugene, OR). Viable cells were
measured using a FACSArray bioanalyzer (BD Biosciences), and
mean fluorescence intensity was graphed using GraphPad PRISM
(GraphPad Software, San Diego, CA).
Scratch wound healing assay in two-dimensional culture
Keratinocytes were grown to confluence and wounded with a
sterile0.1- to 10-ml pipette tip. Six perpendicular linear scratches were
generated and the repopulation of the wound gaps created was
photographed. Differences in cell migration were calculated by
measuring repopulation of the scratch wound after 12 hr when
compared to the original wound edge (time zero). For each condition,
results were expressed as a percent wound closure when compared to
control wounds, (100% closure). Two independent experiments with
a minimum of three observations for each condition were analyzed.
Fabrication of HSE to generate static (non-wounded) and
dynamic (wounded) three-dimensional model
Skin equivalent cultures were generated as previously described
[17].Briefly,toconstructthecollagenmatrix,HDFcellswereadded
to neutralized Type I Collagen (Organogenesis, Canton, MA) to a
final concentration of 2.5610
4 cells/ml; 3 ml of this mixture was
added to each 35 mm well insert of a 6-well plate and incubated for
7 days in media containing DMEM and 10% fetal calf serum until
the collagen gel showed no further shrinkage. At this time, of 5610
5
NHKs were plated directly on a raised, mesa-like area in the center
of the contracted collagen gel. Cultures were submerged in low
calcium epidermal growth media for 2 days, submerged in normal
calcium epidermal growth media for 2 days and raised to the air-
liquid interface by feeding from below at 37uC in 7.5% CO2. The
cultures were wounded 7 days after keratinocytes were seeded onto
the collagen matrix. An additional collagen matrix was fabricated
and used as the substrate onto which the wounded skin equivalents
weretransferred.To generate wounds,skinequivalent cultureswere
removed from the insert membrane, and a 1.2-cm incision that
penetratedtheepidermisand collagenmatrixwascreatedbyusinga
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The wounded tissue was transferred onto the second, previously
fabricated, collagen matrix. Wounded cultures were maintained at
the air–liquid interface for 24, 48, and 72 hr at 37uC in 7.5% CO2
to monitor reepithelialization.
Morphologic analysis and Immunofluorescence staining
For light microscopy, skin equivalent cultures were fixed in 4%
neutral buffered formalin, embedded in paraffin, and serially
sectioned at 8 mm. Sections were stained with hematoxylin and
eosin, and visualized using a Nikon Eclipse 80i microscope
equipped with Diagnostic Instruments SPOT-RT Camera. For
epifluorescence microscopy, tissues were harvested and frozen in
embedding medium (Triangle Biomedical) after being placed in
2 M sucrose overnight at 4uC. Frozen tissues were serially
sectioned at 8 mm and stained with secondary antibodies
(Boehringer-Mannheim) and counterstained with DAPI (4,6-
diamidino-2-phenylindole) (Vector).
Results
ASC-8, but not ASC-3, blocks interaction between b4 and
laminin-5 in human keratinocytes
Expression of a6b4 was detected in the human adult keratinocytes
(NHK) as well as in HaCaT cells, a spontaneously immortalized
human keratinocyte cell line by flow cytometry. The titration of a6b4
using the FACS technique with both antibodies (ASC-3 and ASC-8)
showed strong binding to these cells, demonstrating the constitutive
expression of a6b4 in both cell types. The measured EC50 on these
two types of keratinocytes was higher for HaCaT than NHK for
ASC-3 (NHK: 1.9 nM: HaCaT: 2.6 nM) as well as for ASC-8
(NHK: 0.065 nM; HaCaT: 0.15 nM). (Figure 1a and b)
The b4-specific antibody ASC-8 has previously been shown to
block adhesion to laminin in cells expressing endogenous a6b4 [18].
We therefore examined whether the same response could be
observed for a6b4-expressing keratinocytes. Preincubation of ASC-
8 with either NHK or HaCaT prior to incubationof cells on human
laminin-1 (Figure 1c) or laminin-5-coated plates (Figure 1d) resulted
in complete blockade of endogenous a6b4-laminin interactions.
Interestingly, preincubation with the ASC-3 antibody had no
inhibitory effect on a6b4-laminin interactions similar to the isotype
control. These observations further confirmed the presence of a6b4
integrins on both keratinocyte cell types. Moreover, this demon-
strated that the epitope recognized by ASC-8 plays a critical role in
mediating the adhesive interactions between the b4 subunit with
laminin-5, whereas the epitope recognized by ASC-3 seems to be
irrelevant for cell adhesion.
Blocking inhibition of cell migration in a two-dimensional
scratch assay contains the functional blocking capacity of
ASC-8 antibody
In order to assess possible different effects of the two b4
antibodies on keratinocyte migration, we performed scrape wound
Figure 1. Characterization of b4-specific antibody effects on human keratinocytes. The binding of control or b4-specific antibodies ASC-3
and ASC-8 to normal human keratinocytes (A) and HaCaT cells (B) was measured by flow cytometry. To determine the effects on adhesion, serum
starved cells were either left untreated (NT), or incubated with control or b4-specific antibodies prior to plating on rat laminin-5 (C) and a mixture of
human laminins (D) Relative adhesion was measured using a luciferase based luminescent viability assay. Experiments were performed twice in
triplicate and results shown are from one representative experiment.
doi:10.1371/journal.pone.0010528.g001
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uncoated plates, were mechanically disrupted to create an area
devoid of cells (Figure 2a–c). Wounded cultures were then treated
with one of the antibody at a saturating antibody concentration of
25 mg/ml. When the rate of cell repopulation of the scratch was
measured, both untreated keratinocytes (Figure 2d) as well as
ASC-3 treated cultures (Figure 2e) were found to repopulate the
wound gap 24 hours after wounding. In contrast, ASC-8-treated
cultures did not repopulate the wound gap, as only a few cells were
found to migrate into the wound after 12 hr (Figure 2f). As
summarized in Figure 2g, quantitative analysis of scrape wounds
revealed a significant decrease in the rate of cell migration in ASC-
8 treated cells (29%610.9%) in comparison to ASC-3 treated
(79%61.3) and control untreated cultures (84%62.3). These
results confirmed that this inhibition of keratinocyte migration was
dependent on the epitopes of the blocking antibody, and
that laminin-5-b4 interactions are necessary for keratinocyte
migration.
Antibody blocking of integrin subunit b4i na
non-wounded static three-dimensional human skin
equivalent
In order to test if the blocking of laminin-5-b4 interactions could
lead to morphological differences in the tissues, the HSEs were
incubated with ASC-3 and ASC-8 in the culture medium. No
morphological differences could be detected upon Hematoxilin
and Eosin staining when tissues were incubated with ASC-3 or
ASC-8. (Figure 3a–c). To assess the presence of ASC-3 and ASC-8
in the HSE, the two antibodies were visualized using a secondary
Figure 2. Immunoblocking of integrins decreases the rate of cell motility. The initial scratch wound was carried out on uncoated culture
dishes with confluent keratinocyte cultures (A), and on keratinocyte cultures treated with ASC-3 (B) and ASC-8 (C). Panels D–F illustrate repopulation
of the wound surface after 24 hours by keratinocytes without the presence of antibodies (D), or in the presence of ASC-3 (E), or ASC-8 (F). Cells that
migrated into the wound gap were calculated for each condition and the differences were expressed as a percentage of wound closure of NHK cell
culture (G). Each bar represents the mean and the standard deviation of triplicate determinations in two separate experiments.
doi:10.1371/journal.pone.0010528.g002
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(Fig. 3 red staining). No signal could be detected in the control
HSE lacking antibodies in the culture medium (Fig. 3d) while both
ASC-3 and ASC-8-treated cultures (Fig. 3e and f) demonstrated
antibody localization to the basement membrane interface. The
presence of ASC-3 antibodies was localized to an intact interface
between dermis and epidermis, as seen by the linear stain along
the basement membrane interface. In contrast, the adhesion-
blocking antibody, ASC-8, caused disruption of this interface as
evidenced by a split seen just below the basal keratinocytes
between epidermis and dermis. Laminin-5 and a6 integrin serve as
markers of the degree of organization of the epithelial–stromal
interface. The linear interface deposition of a6 integrin (Figure 4a–
c) and laminin-5 (Figure 4d–f) polarized along the basement
membrane were found in the skin equivalents, in spite of the tissue
disruption. In light of our previous findings that the linear, co-
localization of these proteins was linked to basement membrane
assembly [12,19], this distribution is an indication of the
unperturbed organization of basement membrane in ASC-3
treated tissues and abrogation of basement membrane assembly
in ASC-8 treated tissues.
ASC-8-antibody blocks re-epithelialization in a dynamic
HSE model of wound repair
We next studied the effects of targeting b4 in wounded HSEs,
which faithfully recapitulate the keratinocyte migration and
proliferation seen in cutaneous healing of wounds in vivo.W e
used our previously-developed three-dimensional HSE model of
cutaneous wound repair [13] to determine if blocking b4 integrin
with ASC-3 or ASC-8 could also differentially alter the rate of re-
epithelialization of wounded HSEs. After 24 hours, epithelial
tongues were seen at the edge of the wound margin, indicating re-
epithelialization was initiated at this time. By 48 hours post-
wounding, the wound bed was completely covered by keratino-
cytes and tissue integrity was restored. To determine if the rate of
wound healing differed in the presence of different antibodies, the
distance separating the edge two epithelial tongues was measured
and normalized to the location of the initial wound margins. The
rate of wound closure was assessed by comparing the degree of re-
epithelialization from the wound edge at 48 (Figure 5a,c and e)
and 120 hours (Figure 5b, d and f) after wounding. HSEs
wounded in the presence of ASC-3 (Figure 5c,d) showed a rate
of wound closure similar to control tissues not exposed to antibody
(Figure 5a,b). In contrast, the presence of ASC-8 significantly
reduced the rate of re-epithelialization after 48 hours
(Figure 5e)(Control=100%, ASC-3=9663.2% and ASC-
8=3665.4%) as well as after 120 hours (Figure 5f)
(Control=100%, ASC-3=100% and ASC-8=4261.5%). These
results indicate that disruption of the interactions between laminin-
5 and b4 inhibit wound re-epithelialization when compared to
non-adhesion blocking, anti-b4 antibodies.
Discussion
Integrin a6b4 has been shown to be important for normal tissue
homeostasis through its role in anchoring cells to the basement
Figure 3. Immunodetection of the blocking antibodies in the Human Skin Equivalents. H and E staining of tissues revealed no differences
in tissue architecture or numbers of cell layers between the control (A) and the ASC-3 (B) or ASC-8 (C) treated HSEs. No antibody was detected in the
control tissues not exposed to antibodies. (D). While both ASC-3 (E) and ASC-8 (F) antibodies detected inside the tissue at the junction between
dermis and epidermis, indicating specific localization by target along the basement membrane interface (C and F) ASC-8 is associated with a large
disruption of the tissue integrity between the dermis and epidermis (F, white arrow).
doi:10.1371/journal.pone.0010528.g003
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therapeutic target in human cancer, with established roles in
cancer cell adhesion, migration, and angiogenesis. The dysregu-
lation of this integrin is known to promote tumor growth by
altering the proliferation and migration of epithelial tumor cells
that is mediated by growth factor receptor signaling. Several
studies have linked a6b4 to cooperative signaling with growth
factor receptors, particularly Epidermal growth factor receptor
(EGFR), erythroblastosis oncogene B (ErbB2), and c-Met, through
the Phosphoinositide 3-kinase pathway to facilitate tumorigenesis
[9,20–23]. Mice deficient in the long cytoplasmic domain of b4,
while maintaining functional epithelial adhesion, show drastically
reduced tumor size associated with less vascularization, implicating
b4 in tumor angiogenesis [24]. These studies and others suggest
a6b4 targeted therapy could have broad implications for cancer
therapy, particularly in combination with other targeted agents in
biological pathways, such as EGFR inhibitors, Herceptin
TM
(targeting ErbB2), or Avastin
TM (targeting Vascular endothelial
growth factor). Therefore, a6b4 is an attractive target for antibody
therapy to treat epithelial cancers.
In the current study, we have addressed the safety concerns of
targeting the b4 integrin by using Human Skin Equivalents (HSEs)
as a screening platform to determine if antibodies that target two
different epitopes in the b4 subunit can disrupt the structure or
function of HSEs. Because a6b4 is involved in normal physiolog-
ical processes, such as tissue homeostasis and wound healing, it
was important to use an in vitro tissue model that could recapitulate
these processes in order to test b4 inhibitors in the early drug
discovery process. In addition, these antibodies are specific for
human b4 subunit, and thus require a fully human tissue model for
making safety assessments. Therefore, we chose the well described
HSE tissue model, which recapitulates human skin and wound
healing, to test antibodies directed at b4. Our previous results [15]
demonstrated that the adhesion-blocking antibody ASC-8, had no
effect on anchorage-independent growth of tumor cells, but a non-
adhesion blocking antibody, ASC-3, did inhibit this b4 mediated
function. We have extended these studies to show that ASC-8
disrupts the attachment of basal keratinocytes at the basement
membrane interface and has a profound effect on wound closure
by blocking migration of keratinocytes in the epithelial tongue of
wounded HSEs.
In our study, both laminin-5 and integrin subunit a6 were
distributed along the basement membrane interface in non-treated
and ASC-3-treated samples. Tissues treated with ASC-8 showed a
split beneath the non-wounded epithelium in a pattern in which
laminin-5 was localized both to the epidermal and dermal side of
the basement membrane interface. It is likely that the split seen in
normal HSEs is due to the blocking of b4 integrin by ASC-8. Our
additional results in two-dimensional scratch wound assays,
demonstrating the profound blocking effect of ASC-8, may also
be due to the ability of the blocking antibody ASC-8 to inhibit
keratinocyte migration. Therefore, antibodies to distinct epitopes
of b4 integrin can distinguish between its adhesive functions that
were blocked with ASC-8 and functions not linked to wound
healing or cell migration such as those seen with ASC-3. The
results in the HSE demonstrate that the blocking the interaction of
b4 with laminin-5 could have deleterious consequences. This sub-
basal split seen under the stratum basale was similar to the pattern
previously reported from the skin of patients with junctional
epidermolysis bullosa, in which mutation of the b4 subunit
Figure 4. Immunofluorescent detection of the Basement Membrane Proteins. The immunodetection of alpha6 integrin shows no
difference between the control (A) and the presence of ASC-3 and ASC-8 antibodies in the medium (B and C). The same observation can be made for
laminin-5 (D, E and F). Note that in all cases (C),(F) ASC-8 is associated with large disruption of the tissue between dermis and epidermis (white arrow).
doi:10.1371/journal.pone.0010528.g004
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membrane interface [25,26]. Interestingly, the non-adhesion-
blocking antibody, ASC-3, demonstrated anti-tumor effects in vitro
in our prior studies [15], supporting the conclusion that the
tumorigenic properties of b4 can be targeted independently of the
adhesive properties to laminins.
Our results have broader implications to the drug discovery
process because they also demonstrate the utility of three-
Figure 5. Hematoxylin and Eosin staining of in vitro wound after 48 and 120 hours. Compared to control wounds at 48 h (A) or 120 h (B)
after wounding, with antibody ASC-3, epithelial tongue has covered more than 90% at 48 hour (between arrows) (C) and is totally close after
120 hours (D). However, ASC-8 completely inhibited wound closure (E). Even after 120 hours no wound closure can be observed (F). (E) Percentage of
wound closure (grey bars: closure after 48 hours; black bars: closure after 120 hours). Results from two separate experiments are presented as
mean6SD. Bar: 500 mm.
doi:10.1371/journal.pone.0010528.g005
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therapy in a fully human tissue setting. A greater number of
therapies targeting the tumor microenvironment, such as a6b4,
are being investigated by the pharmaceutical industry, so
understanding the behavior of these drugs in complex biological
systems is information that can not be garnered from traditional
cell culture models [27,28]. Moreover, it is often difficult to test
these new drugs using human antibodies in mouse models due to
lack of cross-reactivity with the murine target. Testing such
antibody candidates in three-dimensional human tissue models
allows predictions of the safety of several candidate molecules long
before preclinical testing in non-human primates or in human
clinical situations [29]. Until recently, experimental paradigms
have been based primarily on two-dimensional, monolayer culture
systems. However, the ability of these approaches to simulate
biological processes in human tissues has been limited, as it is
known that biologically-meaningful signaling pathways function
optimally when cells are spatially organized in three-dimensional
tissues, but are uncoupled and lost in rudimentary two-
dimensional culture systems. As we have shown in the current
study, these three-dimensional tissue platforms are now able to
yield biologically-relevant information that can be adapted to serve
as human, ‘‘pre-clinical’’ or ‘‘surrogate’’ tissues that act as a
translational modality to provide more meaningful correlations
between in vitro screening assays for toxicity and efficacy and in vivo
tissue outcomes in human clinical trials.
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